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Abstract Dendritic cells (DC) are professional antigen-
presenting cells of the immune system that play a key role in
regulating T cell-based immunity. In vivo, the capacity of
DC to activate T cells depends on their ability to migrate to
the T cell areas of lymph nodes as well as on their matura-
tion state. Depending on their cytokine-secreting proWle, DC
are able to skew the immune response in a speciWc direction.
In particular, IL-12p70 producing DC drive T cells towards
a T helper 1 type response. A serious disadvantage of cur-
rent clinical grade ex vivo generated monocyte-derived DC
is the poor IL-12p70 production. We have investigated the
eVects of Toll-like receptor (TLR)-mediated maturation on
ex vivo generated human monocyte-derived DC. We
demonstrate that in contrast to cytokine-matured DC, DC
matured with poly(I:C) (TLR3 ligand) and/or R848 (TLR7/
8 ligand) are able to produce vast amounts of IL-12p70, but
exhibit a reduced migratory capacity. The addition of pros-
taglandin E2 (PGE2) improved the migratory capacity of
TLR-ligand matured DC while maintaining their IL-12p70
production upon T cell encounter. We propose a novel clini-
cal grade maturation protocol in which TLR ligands
poly(I:C) and R848 are combined with PGE2 to generate DC
with both high migratory capacity and IL-12p70 production
upon T cell encounter.
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Abbreviations
CDC Conventional cytokine matured DC 
(matured with IL-1, IL-6, TNF, PGE2)
DC Dendritic cells
HS Human serum
PBL Peripheral blood lymphocytes
PGE2 Prostaglandin E2
Poly(I:C) Polyinosinic:polycytidylic  acid
TLR Toll-like receptor
TLR3-DC TLR3 ligand (poly(I:C)) matured DC
TLR7/8-DC TLR7/8 ligand (R848) matured DC
TLR-DC DC matured with TLR3 ligand (poly(I:C))
and TLR7/8 ligand (R848)
Introduction
Dendritic cells (DC) are highly specialized antigen-present-
ing cells, acting as the sentinels of the immune system [1].
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Immature DC are located in peripheral tissues, where they
capture and process antigens. Pro-inXammatory cytokines
and microbial products, as well as endogenous factors, can
activate immature DC that successively undergo a complex
maturation process. This process is characterized by a
switch in cytokine and chemokine receptors and up-regula-
tion of MHC complexes and co-stimulatory molecules [2].
Upon maturation, DC migrate via the lymphatic vessels to
the secondary lymphoid tissue where they relocate to the T
cell zone of the lymph node [3, 4]. Depending on the stim-
uli received, DC are able to skew naive T cell diVerentia-
tion towards either a T helper 1 (Th1) or Th2 response, thus
orchestrating speciWc immune responses.
Because of their central role in the induction of immu-
nity, ex vivo generated monocyte-derived DC have been
applied in cancer immunotherapy [5–8]. Previous clinical
studies have demonstrated that eVective induction of spe-
ciWc antitumor cytotoxic T cell (CTL) responses require a
mature status of the DC [6, 9]. As the activation of T cells
occurs in secondary lymphoid organs, the capacity of the ex
vivo generated DC to migrate into lymph nodes in vivo
appears to be of crucial importance [10–12]. To date, the
most widely applied DC are monocyte-derived DC that are
ex vivo matured with a deWned cocktail of the pro-inXam-
matory cytokines TNF, IL-1, IL-6 and prostaglandin E2
(PGE2) [13]. This maturation cocktail leads to phenotypi-
cally mature DC with adequate migratory capacities in vitro
and in vivo [14].
PGE2 is included in this maturation cocktail for its par-
ticipation in podosome dissolution and high-speed migra-
tion [15]. Although these DC have shown to be capable of
inducing Th1-type tumor-speciWc immune responses in
vivo [16], they secrete only limited amounts of the Th1
inducing cytokine interleukin-12p70 (IL-12p70). On the
other hand, the presence of PGE2 during maturation of DC
inhibits the production of IL-12p70 [17, 18].
IL-12p70 production enhances the ability of DC to
induce tumor speciWc IFN producing Th1 cells and CTL
and, thereby, the ability to mount an adequate anti-tumor
response in vivo [19]. Furthermore, in vitro studies indi-
cated that IL-12p70 positively inXuences the properties of
CD8+ T cells to become memory cells and to recruit natural
killer (NK) cells [20, 21]. From preclinical studies it is sug-
gested that inadequate IL-12p70 production is one of the
hurdles to take in improving the clinical outcomes in cancer
immunotherapy studies [22–24].
TLR are innate receptors that sense microbial and viral
products and trigger DC maturation and cytokine produc-
tion [25, 26]. Triggering Toll-like receptors (TLR) on DC
induces high IL-12p70 production [27]. In mice, the matu-
ration of DC by pro-inXammatory cytokines yields DC that
support T cell clonal expansion, but fail to eYciently direct
eVector T cell diVerentiation [28]. Interestingly, DC
matured in the presence of TLR ligands were able to induce
full T cell eVector function and unleashed more potent
immune responses [29]. Moreover, cross-presentation of
exogenous antigen in MHC class I is enhanced in the pres-
ence of TLR ligands [30].
Monocyte-derived DC express TLR3, TLR4, TLR7,
TLR8 and TLR 9 [31,  32]. In 2004, Mailliard et al. [22]
developed a clinical grade maturation cocktail to obtain the
so-called alpha-type 1 polarized DC, by including IFN and
the TLR3 ligand polyinosinic:polycytidylic acid (poly(I:C))
in addition to IL-1, TNF and IFN. The addition of
poly(I:C), a viral dsRNA mimic, to the pro-inXammatory
cytokine maturation cocktail dramatically increases the IL-
12p70 production and subsequently the number of tumor-spe-
ciWc CTL in vitro [22, 33]. The TLR7/8 ligand R848 belongs
to the imidazoquinolines family and also strongly induces the
production of IL-12p70 [34]. Napolitani et  al. [27] showed
that the combination of TLR3 and TLR7/8 ligands leads to a
synergistic IL-12p70 production by DC. However, TLR-
ligand matured DC have an altered expression of regulator of
G protein signaling proteins, which may negatively aVect the
chemotaxis and migration of these cells [35].
DC used for clinical vaccination studies require both
migratory and cytokine production capacities. Currently, no
clinical grade maturation protocol is available that yields DC
that combines these desired features. In this study we investi-
gated the application of TLR ligands in ex vivo maturation of
DC and propose a clinically applicable maturation protocol
consisting of two TLR ligands and PGE2, to generate DC that
Wt the desired physiological role of migration to the lymph
nodes and IL-12p70 production upon T cell contact to induce
tumor speciWc IFN producing Th1 cells and CTL.
Materials and methods
Antibodies and immunostaining
The phenotype of the DC populations was determined by
Xow cytometry. The following primary monoclonal anti-
bodies (mAbs) or the appropriate isotype controls were
used: anti-HLA-ABC (W6/32), anti-HLA DR/DP (Q5/13)
and anti-CD80 (all Becton Dickinson, Mountain View, CA,
USA); anti-CD83 (Beckman Coulter, Mijdrecht, the Neth-
erlands), anti-CD86 (Pharmingen, San Diego, CA, USA);
anti-CCR7 (kind gift of Martin Lipp, Max Planck Institute,
Berlin, Germany), anti-CD14 (Beckman Coulter) followed
by Goat-anti-Mouse FITC (Roche).
Culture media and cytokines 
For DC culture, X-VIVO 15 (BioWhittaker, Walkersville,
MD, USA) was supplemented with 2% human serum (HS;Cancer Immunol Immunother (2008) 57:1589–1597 1591
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serum of six blood donors type AB was pooled) (Sanquin,
Bloodbank Zuid-Oost, Nijmegen, the Netherlands), IL-4
(300 U/ml) and GM-CSF (450 U/ml) (both from Strath-
mann, Hamburg Germany). For maturation the following
products were used: recombinant TNF (10 ng/ml; CellGe-
nix, Freiburg, Germany), IL-1 (5 ng/ml or 25 ng/ml;
Immunotools, Friesoythe, Germany), PGE2 (10 g/ml)
(Pharmacia & Upjohn, Puurs, Belgium), IL-6 (15 ng/ml)
(CellGenix), IFN (10,000 U/ml) (Roche, Mijdrecht, the
Netherlands), IFN (1000 U/ml) (Roche), poly(I:C) (20 g/
ml) (Sigma Chemicals Co., St Louis, MO), R848 (3 g/ml)
(PharmaTech, Shanghai, China). 
Generation of mature DC 
BuVy coats were obtained from healthy volunteers accord-
ing to institutional guidelines. Monocytes were isolated
from peripheral blood mononuclear cells (PBMC) by
adherence, as described previously [36]. On day 6 or day 7,
cells were harvested (immature DC) or maturation cocktail
was added for 48 h, after which the cells were harvested.
Migration assay
Flat-bottomed 96-well plates (Costar, Corning Inc. Corn-
ing, NY) were coated with 50 l/well Wbronectin (20 g/
ml; Roche) for 60 min at 37°C, washed with PBS and
blocked with 100 l/well 0.01% gelatin (Sigma) for 30 min
at 37°C. Totally 4,000 DC/well were seeded and recorded
for 60 min at 37°C, after which migration tracks of individ-
ual DC were analyzed using an automated cell tracking sys-
tem [37].
Transwell migration assay 
Chemotaxis of DC in response to CCL21 (a ligand for the
CCR7 chemokine receptor) was measured in 24-well
plates carrying transwell permeable supports with 5 m
pore size polycarbonate membrane (Costar). BrieXy, cul-
ture medium alone or supplemented with 1–100 ng/ml
CCL21 (R&D Systems, Minneapolis, MN) was placed in
the lower compartment in a total volume of 600 l, and 105
DC were loaded into the inserts in 100 l. Kinesis was
determined by measuring the migration in the presence of
chemokine in both the lower and upper compartments.
Chambers were incubated for 120 min in a 5% CO2, humid-
iWed in a incubator at 37°C. Thirty minutes before the end,
5 mM EDTA was added to the lower compartment. Cells
were harvested, centrifugated and resuspended in 100 l
PBS. The number of migrated DC (lower chamber) was
determined by Xow cytometry by acquiring events for a
Wxed time period of 60 s (FACScan, Becton Dickinson).
All conditions were tested in duplicate.
IL-12p70 production
The production of IL-12p70 was measured in the superna-
tants harvested 48h after maturation (1 £ 106 immature
DC (day 3) in 2 ml per well were matured at day 6 with
250 l of the indicated maturation cocktails), or 24 h after
CD40L stimulation (5 £ 103cells/100 l) and mixed lym-
phocyte reaction (MLR: DC:T cell ratio of 1:5 with
100.000 PBL, Wnal volume 100 l) using a standard sand-
wich ELISA (Pierce Biotechnology, Rockford). The pro-
cedure was performed according to the manufacturer’s
instructions.
Allogeneic MLR
The allostimulatory capacity of the DC was tested in a
mixed lymphocyte reaction (MLR). Allogeneic T cells
were co-cultured with diVerently matured DC in a 96-well
tissue culture microplate (DC:T cell ratio 1:5 with
100.000 PBL). After 24 h the cytokines in the supernatant
were analyzed with a cytometric bead array for human Th1/
Th2 cytokines (BD Biosciences, San Diego, CA) according
to the manufacturer’s instructions (detecting IL-2, IL-4,
IL-5, IL-10, TNF and IFN).
CD40L stimulation
DC were harvested, washed and seeded in a 96-well round-
bottomed plate at 50 £ 103 cells in 100 l per well. To
mimic the interaction with CD40L-expressing Th-cells,
CD40 L trimers (Leinco Technologies, Missouri, USA)
were added at a concentration of 1 g/ml. Twenty-four-
hour supernatants were analyzed by IL-12p70 ELISA.
Antigen-speciWc proliferation assay
Cellular responses against the protein keyhole limpet
hemocyanin (KLH) were measured in a proliferation
assay. In our vaccination studies, KLH is added to the
immature DC culture as a immunomonitoring tool.
Peripheral blood mononuclear cells (PBMC) were iso-
lated from blood sample from four patients taken after
four biweekly vaccinations with mature DC. CD4+ T cells
were isolated with a CD4+ T cell isolation kit (Miltenyi
Biotech, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. The puriWed T cells were
plated in a 96-well tissue culture microplate with autolo-
gous DC that were cultured with or without KLH and
matured with the cytokine cocktail or with poly(I:C) and
R848 with or without PGE2. After 4 days of culture,
1 Ci/well of tritiated thymidine was added for 8 h, and
incorporation of tritiated thymidine was measured in a
beta-counter.1592 Cancer Immunol Immunother (2008) 57:1589–1597
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Statistics
Data were analyzed using unpaired Student t-test, p-values
<0.05 were considered to be statistically signiWcant.
Results and discussion
To Wnd the optimal maturation procedure to generate DC
that have both migratory and IL-12p70 producing capaci-
ties, we compared the eVect of various maturation cock-
tails. Cytokine matured DC that are conventionally used in
clinical studies were compared with DC matured with
poly(I:C) or R848 or both. Pro-inXammatory cytokines
such as TNF, IFN and IFN can further enhance the IL-
12p70 production [22, 27, 38, 39], however, the eVect on
migratory capacity of DC is unknown. In an eVort to
improve the migration of TLR-ligand matured DC, while
maintaining IL-12p70 production we tested the eVect of
these pro-inXammatory cytokines and PGE2. Monocyte-
derived DC were, thus, matured as follows: (1) conven-
tional-DC (cDC), matured with the pro-inXammatory cock-
tail (IL-1, IL-6, TNF, PGE2) as described by Jonuleit
et al. [13], (2) Toll-like receptor DC (TLR-DC), matured
with TLR-ligands alone (poly(I:C), R848, or both; respec-
tively TLR3-DC, TLR7/8-DC or TLR-DC), or (3)
poly(I:C) and R848 in combination with pro-inXammatory
cytokines (TNF, IFN or IFN; respectively TNF-TLR-
DC, IFN-TLR-DC and IFN-TLR-DC) or prostaglandin
E2 (PGE2-TLR-DC).
TLR-ligands and pro-inXammatory cytokines induce DC 
with a mature phenotype
We Wrst compared the eVect of the diVerent maturation
cocktails on the morphology and phenotype of the DC.
cDC had the characteristic semi-round appearance with
multiple dendrites. In contrast, both TLR3-DC, TLR7/8-
DC and TLR-DC showed a more elongated morphology
and were more adherent to plastic than cDC (Fig. S1a in
electronic supplementary material). Although they all
expressed the maturation markers CD80, CD86 and
MHC class II (Fig. 1a), the expression of CD83 using the
TLR ligands alone for maturation was slightly decreased
in comparison with the cDC cocktail and the combina-
tion of the TLR-ligands. The increased adherence was
reXected in a slightly lower yield and viability of espe-
cially TLR7/8-DC and TLR-DC (Fig. S1b in ESM).
Addition of a pro-inXammatory cytokines to the DC
matured with TLR-ligands did not change the morphol-
ogy of the DC. On the contrary, DC cultured with TLR
ligands in the presence of PGE2 were more similar to
cDC (Fig. S1a in ESM).
All diVerent maturation cocktails generate phenotypi-
cally mature DC, expressing MHC class I and II, co-stimu-
latory molecules (CD80, CD86), DC-maturation marker
CD83 and chemokine-receptor CCR7, which is consistent
with previously published data for the above-mentioned
maturation cocktails [6, 22, 27]. These phenotypes were
stable and did not change when the maturation cocktail was
removed after 48 h and cells were cultured in fresh medium
without maturation stimuli over the next 72 h (data not
shown).
Fig. 1 Phenotype and IL-12p70 production after DC maturation with
diVerent cocktails. Immature DC were matured for 48 h with diVerent
maturation cocktails, maturation markers were evaluated by Xow
cytometry and IL-12p70 secreted was measured in the supernatant by
ELISA. a DC from three diVerent donors matured with the conven-
tional cytokine cocktail (TNF, IL-6, IL-1 and PGE2), TLR3 ligand
poly(I:C), TLR7/8 ligand (R848) or both. Upper panels show the
diVerent maturation cocktails used. Horizontally the expression of
CD80, CD83, CD86, CCR7 and MHC class II from one representative
donor measured by Xow cytometry is shown (bold line). The thin line
represents the isotype control. The lower panel shows the IL-12p70
production in the supernatant measured by ELISA. b DC from diVerent
donors were matured with the conventional cytokine cocktail (TNF,
IL-6, IL-1 and PGE2), or poly(I:C) or R848 or poly(I:C)/R848 in the
combination with TNF, IFN, IFN with and without PGE2. IL-
12p70 production was measured after 48 h. Per condition each symbol
represents one donor. Means are shown for each maturation cocktail
and were compared to cDC (* p < 0.05), comparison of the diVerent
cocktails with TLR-DC were signiWcant with all the diVerent cocktails.
There is no signiWcant diVerence between PGE2-TLR-DC and the
TNF/IFN/IFN-PGE2-TLR-DC
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IL-12p70 production is dramatically increased 
by TLR-ligands and hampered by PGE2 
IL-12p70 secreted by mature DC skews the eVector
response towards Th1 type and recruits memory T cells and
NK cells. Upon TLR-triggering, DC rapidly produce high
levels of IL-12p70 [27]. So, we examined the IL-12p70
production 48 h after addition of the diVerent maturation
factors. As reported before [22], cDC hardly produce any
IL-12p70 (Fig. 1b). DC matured with poly(I:C) or R848 pro-
duced elevated levels of IL-12p70, which was further
boosted when these ligands were combined (Fig. 1b), con-
Wrming the synergistic eVect described by Napolitani et al.
[27], which presumably results from concurrent triggering of
the intracellular signaling pathways via both MyD88 and
TRIF. We found that TLR-DC produce the majority of IL-
12p70 within 24 h, while little is produced in the next 24 h
(data not shown). The addition of IFN or IFN boosted the
IL-12p70 production even further (Fig. 1b). IFN appeared
to be the most potent inducer of stable IL-12p70 production,
as it resulted in a Wvefold increase in IL-12p70 production.
As expected [17], the addition of PGE2 signiWcantly reduced
the IL-12p70 production (Fig. 1b). Thus, also in clinical
grade DC preparations, poly(I:C) and R848 strongly induce
IL-12p70 secretion during maturation, which is enhanced by
type I and II interferons and inhibited by PGE2.
Migration of TLR-DC is poor and restored 
by the addition of PGE2
cDC exhibit known high migratory capacity in vitro and in
vivo [22], but do not produce IL-12p70. In contrast, DC
matured with poly(I:C) and/or R848 produce high levels of
IL-12p70 [22, 27, 34]. According to Luft et al. [18] mature
DC diVerentiate in either migratory or cytokine secreting
cells. For immunotherapy with DC, both qualities are of
crucial importance for the induction of potent immune
responses. Therefore, we compared the migratory capacity
of cDC with TLR-ligand matured DC and tested the eVect
of diVerent cytokines and PGE2. Random migration of indi-
vidual DC on Wbronectin was analyzed using an automated
cell-tracking system [37]. The migrated distance in 1 h of
the TLR-DC was signiWcantly lower compared to the cDC
(Fig. 2a). Detailed analysis of individual cells indicated that
the activity of the cells (percentage of time migrating) was
signiWcantly lower in all TLR-ligand matured DC (Fig. 2b).
The addition of TNF, IFN or IFN to the TLR-DC had no
eVect (Fig. 2). The addition of PGE2 to the diVerent matura-
tion cocktails markedly restored the motility of DC in all
combinations (Fig. 2; Fig. S2 in ESM), indicating that PGE2
stimulates also the motility of TLR-ligand matured DC.
PGE2 is known for its favorable eVect on the migratory
capacity of DC. It has a critical role in podosome dissolution
and induction of high-speed migration [15]. PGE2 can
accomplish both the expression and activation of CCR7, that
allows DC to eYciently migrate towards the lymph node in
response to CCL19 [23] and CCL21 [24]. The morphology
of our cells upon maturation suggests that the inclusion of
PGE2 in the maturation cocktail results in less adherent cells
(Fig. S1a in ESM) what may favor migration. FACS analy-
sis showed that CCR7 expression was more upregulated on
cDC and PGE2-TLR-DC compared to TLR-DC (Fig. 3a). In
addition, cDC and PGE2-TLR-DC but not TLR-DC
migrated similarly towards CCL21 in a chemotaxis assay
(Fig. 3b), demonstrating that CCR7 was expressed in an
active form. Thus, unlike the pro-inXammatory cytokines
Fig. 2 Migration of the TLR-ligand DC is poor and can be restored
upon addition of PGE2. DiVerently matured DC from three to six diVer-
ent donors were added to a Wbronectin-coated plate and individual cells
were monitored for 60 min for their motility. The migrated distance (in
m) (a) and the activity (the percentage of time the cells were migrat-
ing) (b) is plotted for the diVerent maturation cocktails and compared
to cDC. Per condition, each symbol represents the mean for each donor
(individual donors indicated by diVerent symbols). Means are shown
for each maturation cocktail and were compared to cDC
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TNF, IFN and IFN, PGE2 appears to be critical for den-
dritic cell migration, resulting in comparable motility and
chemotactic capabilities of PGE2-TLR-DC and cDC.
Recently, Lehner et al. [40] showed that DC matured with
only Poly(I:C) or R848 are also capable of CCR7-mediated
migration, although the number of migrated cells was lower
and the cells were strongly adherent. We show here that add-
ing PGE2 to the combination of Poly(I:C) and R848 gener-
ated mature DC that do not only show CCR7-mediated
migration but are also less adherent and highly migratory.
PGE2 does not inhibit secondary IL-12p70 in TLR-ligand 
matured DC
In clinical vaccination studies, DC should produce IL-
12p70 after migration to the lymph nodes and upon
subsequent T cell contact [40, 41]. At this time point, local
and probably low levels of IL-12p70 in the contact area
between DC and T cells may suYce to direct naive T cells
towards Th1. Moreover, low levels of IL-12p70 will pre-
vent aspeciWc activation of T cells in the microenvironment
of the DC. Importantly, IL-12p70 production was not
detectable when mature TLR-DC and PGE2-TLR-DC were
cultured for another 24 h in fresh medium without stimuli
(Fig. 4). To test the ability to produce IL-12p70 upon T cell
encounter, we cultured diVerently matured DC in the pres-
ence of allogeneic peripheral blood lymphocytes (PBL).
cDC demonstrated a very low IL-12p70 producing capacity
as shown previously by Mailliard et al. [22], whereas TLR-
DC produced IL-12p70 (Fig. 4). Interestingly, the produc-
tion of IL-12p70 by PGE2-TLR-DC equaled that of TLR-
DC, matured without PGE2.
This increased production of IL-12p70 after T cell stim-
ulation might be explained by a feedback loop: DC–T cell
interaction via CD40–CD40 L triggers the DC to secrete
IL-12p70, which activates and attracts T cells but also NK
cells to produce IFN [42], which can in return stimulate
the DC to produce more IL-12p70. To test the hypothesis
that production of IL-12p70 upon T cell encounter depends
on CD40-ligation, diVerently matured DC were stimulated
for 24 h with CD40L-trimers. Indeed, stimulation of PGE2-
TLR-DC with CD40L-trimers increased the production of
IL-12p70 (Fig. 4). Thus, upon either PBL or CD40L stimu-
lation, PGE2-TLR-DC and TLR-DC produce similar levels
Fig. 3 CCR7 expression and CCR7-mediated chemotaxis of cDC,
TLR-DC and PGE2-TLR-DC. DC from three diVerent donors were
matured with the conventional cytokine-cocktail or with poly(I:C),
R848 with or without PGE2. a CCR7 expression of the diVerent ma-
tured DC and CD80, CD83, CD86 and MHC class II expression of
PGE2-TLR-DC measured by Xowcytometry is shown. b Chemotaxis
was determined by the number of cells that had migrated into the lower
compartment of a transwell system containing increasing concentra-
tions of CCL21, counted in 1 minute by Xow cytometry. Kinesis was
determined by the number of cells that had migrated into the lower
compartment when CCL21 is present in both compartments in the
same concentration. The graph shown here is representative for three
diVerent donors. The error bars show the standard deviation
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of IL-12p70 enabling skewing of the T cell response
towards Th1.
To check whether the secondary production of IL-12p70
upon T cell contact indeed induces a Th1 type eVector
response, we analyzed the supernatants from co-cultures of
cDC, TLR-DC and PGE2-TLR-DC with PBL. It was dem-
onstrated before, that cDC induce expansion of T cells and
which subsequently secrete a broad array of cytokines, e.g.
IL-2 and IFN [13]. Indeed, cDC induced the secretion of
low levels of IFN by the PBL. Importantly, IFN produc-
tion was approximately nine times higher when PBL were
stimulated by TLR-ligand matured DC, both TLR-DC and
PGE2-TLR-DC (Fig. 5a). Secretion of Th2-directive IL-4
and IL-5 was comparable. Although TLR-ligand matured
DC stimulated the secretion of IL-10, this secretion was
decreased when PGE2 was present during maturation. Thus,
indeed TLR-DC and PGE2-TLR-DC generated a more pro-
nounced Th1 response. Both cDC, TLR-DC and PGE2-
TLR-DC are capable of stimulating antigen-speciWc T cells
demonstrated by the KLH-speciWc proliferation of CD4+ T
cells isolated from patients that had been vaccinated previ-
ously with KLH-loaded DC (Fig. 5b).
Conclusion
Human DC consist of a heterogeneous population of cells
that can be classiWed either according to their phenotype or
to their function. It has been postulated that at a certain time
point in their maturation, DC enter a crossroad where their
fate, migratory-type or cytokine producing-type, is
determined. The involved factors, as described above (pro-
inXammatory cytokines, PGE2, TLR ligands, CD40 L) at
least demonstrate the possibility to modulate the properties
of ex vivo generated DC. In a physiological situation these
factors act on this process in the right time, at the right
place, resulting in eVective immune responses. Since vacci-
nations in cancer immunotherapy are an artiWcial situation,
the DC used should potentially perform all the tasks
needed. Our data show that the combination TLR3 and
TLR7/8 ligands together with PGE2, results in clinical
grade mature and stable DC with a high migratory capacity
and maintained IL-12p70 producing capacity. These DC Wt
the desired physiological role of migration to the lymph
node and IL-12p70 production upon T cell contact to
induce tumor speciWc IFN-producing Th1 cells and CTL.
Future studies are needed to demonstrate whether this
migratory potential indeed results in more eYcient migra-
tion of DC into the lymph nodes and improved immune
responses in cancer patients.
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